JP2011506328A5 - - Google Patents

Download PDF

Info

Publication number
JP2011506328A5
JP2011506328A5 JP2010537016A JP2010537016A JP2011506328A5 JP 2011506328 A5 JP2011506328 A5 JP 2011506328A5 JP 2010537016 A JP2010537016 A JP 2010537016A JP 2010537016 A JP2010537016 A JP 2010537016A JP 2011506328 A5 JP2011506328 A5 JP 2011506328A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
peptide
composition according
seq
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010537016A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011506328A (ja
JP5520230B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/085280 external-priority patent/WO2009076105A2/en
Publication of JP2011506328A publication Critical patent/JP2011506328A/ja
Publication of JP2011506328A5 publication Critical patent/JP2011506328A5/ja
Application granted granted Critical
Publication of JP5520230B2 publication Critical patent/JP5520230B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010537016A 2007-12-05 2008-12-02 内在化ペプチドに連結された薬剤と抗炎症剤との共投与 Expired - Fee Related JP5520230B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99267807P 2007-12-05 2007-12-05
US60/992,678 2007-12-05
PCT/US2008/085280 WO2009076105A2 (en) 2007-12-05 2008-12-02 Co-administration of an agent linked to an internalization peptide with an anti-inflammatory

Publications (3)

Publication Number Publication Date
JP2011506328A JP2011506328A (ja) 2011-03-03
JP2011506328A5 true JP2011506328A5 (https=) 2012-02-16
JP5520230B2 JP5520230B2 (ja) 2014-06-11

Family

ID=40756064

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010537016A Expired - Fee Related JP5520230B2 (ja) 2007-12-05 2008-12-02 内在化ペプチドに連結された薬剤と抗炎症剤との共投与

Country Status (14)

Country Link
US (1) US8080518B2 (https=)
EP (1) EP2229185B8 (https=)
JP (1) JP5520230B2 (https=)
CN (1) CN101970011B (https=)
AU (1) AU2008335490B2 (https=)
BR (1) BRPI0820912B1 (https=)
DK (1) DK2229185T3 (https=)
ES (1) ES2555524T3 (https=)
HR (1) HRP20151312T1 (https=)
HU (1) HUE027216T2 (https=)
PL (1) PL2229185T3 (https=)
PT (1) PT2229185E (https=)
SI (1) SI2229185T1 (https=)
WO (1) WO2009076105A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
US7595297B2 (en) * 1999-06-02 2009-09-29 Michael Tymianski Method of reducing injury to mammalian cells
WO2008008348A2 (en) * 2006-07-11 2008-01-17 Arbor Vita Corporation Method and compositions for treating stroke with fever
US8008253B2 (en) 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
CN102088990A (zh) * 2008-05-16 2011-06-08 阿尔伯维塔公司 癫痫的治疗
CN102202677A (zh) 2008-09-03 2011-09-28 阿尔伯维塔公司 治疗疼痛的活性剂和方法
PT2440230T (pt) 2009-06-10 2021-02-03 Nono Inc Regimes de tratamento para tratamento de doenças neurológicas
CA3018494C (en) * 2009-06-10 2021-12-07 Nono Inc. Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
WO2011038397A2 (en) * 2009-09-28 2011-03-31 Duke University Peptide adjuvants, vaccines, and methods of use
US20130052198A1 (en) * 2010-03-29 2013-02-28 The General Hospital Corporation Anti-inflammatory factors
CA2802207C (en) * 2010-06-10 2018-10-30 Indiana University Research And Technology Corporation Materials and method for suppressing inflammatory and neuropathic pain
ES2655112T3 (es) * 2010-08-12 2018-02-16 Nono Inc. Tratamiento de una lesión penetrante en el cerebro
ES2544573T3 (es) * 2011-05-13 2015-09-01 Københavns Universitet (University Of Copenhagen) Inhibidores diméricos de afinidad elevada de PSD-95 y su uso para el tratamiento del daño cerebral isquémico y del dolor
EP2723363B1 (en) 2011-06-24 2018-08-29 NoNO Inc. Combination therapy for ischemia
SG11201406142XA (en) 2012-03-27 2014-10-30 Univ Duke Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
PL2925338T3 (pl) * 2012-11-28 2019-11-29 Nono Inc Liofilizowana formulacja TAT-NR2B9C
US9783586B2 (en) * 2013-03-15 2017-10-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the linear ubiquitin chain assembly complex (LUBAC) and related methods
US20140349944A1 (en) * 2013-05-23 2014-11-27 Musc Foundation For Research Development Chaperone-based integrin inhibitors for the treatment of cancer and inflammatory diseases
PT2946765T (pt) 2014-05-23 2016-11-10 Ares Trading Sa Composição farmacêutica líquida
ES2572919T3 (es) 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
EP2946767B1 (en) 2014-05-23 2016-10-05 Ares Trading S.A. Liquid pharmaceutical composition
WO2016049280A1 (en) * 2014-09-24 2016-03-31 Memorial Sloan Kettering Cancer Center mTORC1 MODULATION
JP7073486B2 (ja) 2017-09-30 2022-05-23 ▲拝▼西欧斯（北京）生物技▲術▼有限公司 興奮性神経毒性に関連した損傷の治療用ペプチド組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034468A2 (en) * 1998-12-11 2000-06-15 Biomira Inc. Muc-1 antagonists and methods of treating immune disorders
US20040226056A1 (en) * 1998-12-22 2004-11-11 Myriad Genetics, Incorporated Compositions and methods for treating neurological disorders and diseases
US20060148711A1 (en) * 1999-05-14 2006-07-06 Arbor Vita Corporation Molecular interactions in neurons
US7595297B2 (en) * 1999-06-02 2009-09-29 Michael Tymianski Method of reducing injury to mammalian cells
DE60026313D1 (de) * 1999-07-23 2006-04-27 Uutech Ltd Sensibilisierung von roten blutkörperchen gegenüber ultraschall durch einwirkung eines elektrischen feldes
US6593292B1 (en) * 1999-08-24 2003-07-15 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6864355B1 (en) * 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
US20020032154A1 (en) * 2000-06-07 2002-03-14 Peyman John A. Interferon-suppressing placental lactogen peptides
WO2003024389A2 (en) * 2001-07-30 2003-03-27 Immunex Corporation T. reesei phytase enyzmes, polynucleides encoding the enzymes, vectors and host cells thereof, and methods of using
EP1601380A1 (en) * 2003-02-13 2005-12-07 Licentia OY Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia
US7947645B2 (en) * 2004-09-02 2011-05-24 Cognosci, Inc. APO E analogs and methods for their use
US7151084B2 (en) * 2004-12-27 2006-12-19 Miller Landon C G Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes
WO2009006611A1 (en) * 2007-07-03 2009-01-08 Arbor Vita Corporation Small molecule inhibitors of pdz interactions
CA2694046C (en) * 2007-07-26 2023-09-12 Revance Therapeutics, Inc. Cationic peptides and compositions thereof
ES2328776B1 (es) * 2007-11-19 2010-07-06 Proyecto De Biomedicina Cima S.L. Peptidos con capacidad para unirse a escurfina y aplicaciones.
CA3018494C (en) 2009-06-10 2021-12-07 Nono Inc. Co-administration of an agent linked to an internalization peptide with an anti-inflammatory

Similar Documents

Publication Publication Date Title
JP2011506328A5 (https=)
HRP20151312T1 (hr) Ko-administracija sredstva vezanog na tat internalizacijski peptid s protuupalnim sredstvom
JP2012530060A5 (https=)
US8933013B2 (en) Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
JP2014527040A5 (https=)
Lei et al. The novel Nrf2 activator CDDO‐EA attenuates cerebral ischemic injury by promoting microglia/macrophage polarization toward M2 phenotype in mice
Tang et al. Tanshinone IIA ameliorates bleomycin-induced pulmonary fibrosis and inhibits transforming growth factor-beta-β–dependent epithelial to mesenchymal transition
JP2012176978A5 (https=)
JP2005506370A5 (https=)
JP2015057436A5 (https=)
EA200971130A1 (ru) Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
NZ600790A (en) Combination therapy for copd
WO2011047097A3 (en) Inhibition of trem receptor signaling with peptide variants
AR079706A1 (es) Composiciones, metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis y uso
JP2015522264A5 (https=)
JP2014516942A5 (https=)
JP2010536714A5 (https=)
UY30461A1 (es) Composicion farmacéutica para la anticoncepcion y para reducir el riesgo de malformaciones congénitas.
JP2011528334A5 (https=)
Hill et al. Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study
WO2009047826A2 (en) Pharmaceutical composition comprising sucralphate and mesalazine
Urakov et al. Inflammation, infiltration, necrosis, abscess and Nicolau syndrome after injection of nonsteroidal anti-inflammatory drugs: What is the reason?
Hawley et al. Switching stable patients with schizophrenia from depot and oral antipsychotics to long‐acting injectable risperidone: reasons for switching and safety
CN103585153B (zh) Caesanines D在治疗和预防肾纤维化药物中的应用
WO2006043260A3 (en) Orally effective cannabinoid analogs